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Auxora versus standard of care for the
treatment of severe or critical COVID-19
pneumonia: results from a randomized
controlled trial
Joseph Miller1†, Charles Bruen2†, Michael Schnaus2,3,4, Jeffrey Zhang5, Sadia Ali3, April Lind3, Zachary Stoecker3,
Kenneth Stauderman6 and Sudarshan Hebbar6*

Abstract
Background: Calcium release-activated calcium (CRAC) channel inhibitors stabilize the pulmonary endothelium and
block proinflammatory cytokine release, potentially mitigating respiratory complications observed in patients with
COVID-19. This study aimed to investigate the safety and efficacy of Auxora, a novel, intravenously administered
CRAC channel inhibitor, in adults with severe or critical COVID-19 pneumonia.
Methods: A randomized, controlled, open-label study of Auxora was conducted in adults with severe or critical
COVID-19 pneumonia. Patients were randomized 2:1 to receive three doses of once-daily Auxora versus standard of
care (SOC) alone. The primary objective was to assess the safety and tolerability of Auxora. Following FDA guidance,
study enrollment was halted early to allow for transition to a randomized, blinded, placebo-controlled study.
Results: In total, 17 patients with severe and three with critical COVID-19 pneumonia were randomized to Auxora and
nine with severe and one with critical COVID-19 pneumonia to SOC. Similar proportions of patients receiving Auxora
and SOC experienced ≥ 1 adverse event (75% versus 80%, respectively). Fewer patients receiving Auxora experienced
serious adverse events versus SOC (30% versus 50%, respectively). Two patients (10%) receiving Auxora and two (20%)
receiving SOC died during the 30 days after randomization. Among patients with severe COVID-19 pneumonia, the
median time to recovery with Auxora was 5 days versus 12 days with SOC; the recovery rate ratio was 1.87 (95% CI,
0.72, 4.89). Invasive mechanical ventilation was needed in 18% of patients with severe COVID-19 pneumonia receiving
Auxora versus 50% receiving SOC (absolute risk reduction = 32%; 95% CI, − 0.07, 0.71). Outcomes measured by an 8point ordinal scale were significantly improved for patients receiving Auxora, especially for patients with a baseline
PaO2/FiO2 = 101–200.
(Continued on next page)
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Conclusions: Auxora demonstrated a favorable safety profile in patients with severe or critical COVID-19 pneumonia
and improved outcomes in patients with severe COVID-19 pneumonia. These results, however, are limited by the
open-label study design and small patient population resulting from the early cessation of enrollment in response to
regulatory guidance. The impact of Auxora on respiratory complications in patients with severe COVID-19 pneumonia
will be further assessed in a planned randomized, blinded, placebo-controlled study.
Trial registration: ClinicalTrials.gov, NCT04345614. Submitted on 7 April 2020.
Keywords: COVID-19 pneumonia, Calcium release-activated calcium channel inhibitors, CRAC channel inhibitors,
Proinflammatory response, Pulmonary endothelium, Respiratory complications

Background
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the disease
COVID-19, was first identified in December 2019 and
designated a global pandemic by the World Health
Organization in February 2020 [1]. The majority of
COVID-19 cases are mild, but up to 20% of patients develop severe or critical pneumonia, manifested by hypoxemia or respiratory failure necessitating mechanical
ventilation, respectively [1, 2]. COVID-19 pneumonia
presents with a constellation of symptoms including
fever, cough, and dyspnea, with infiltrates usually noted
on lung imaging [1, 2]. While the pathophysiology for
COVID-19 pneumonia remains under investigation,
there is an increasing body of literature to suggest a
multifactorial lung injury and the important role of a
hyperinflammatory state in its development [3–5].
Among patients with COVID-19 pneumonia, viral infiltration has been shown to cause severe endothelial injury and diffuse alveolar damage [2–5]. Furthermore,
there appears to be an increase in proinflammatory cytokines leading to additional lung injury [2–5]. Together,
these factors contribute to clinical deterioration, the
need for invasive mechanical ventilation, and, in a substantial proportion of patients, death [2–5].
Evidence suggests that calcium release-activated calcium (CRAC) channels play a role in inflammationinduced injury of pulmonary endothelial cells, resulting
in loss of alveolar-capillary barrier function and extravasation of fluid into the alveoli [6–9]. CRAC channel activation is also linked to the production of
proinflammatory cytokines associated with worsened
outcomes in COVID-19 [7–11]. Thus, inhibition of
CRAC channels may be beneficial in preserving pulmonary endothelial integrity, reducing proinflammatory cytokine levels, and improving oxygenation in patients with
COVID-19 pneumonia [8, 11–14].
CM4620 is a potent and selective CRAC channel inhibitor [11–13, 15]. Preclinical work has demonstrated
that in acute inflammatory conditions, CM4620 reduces
inflammatory signals in the lung, protects tissues from
calcium-induced damage, and lowers serum and

pulmonary proinflammatory cytokine levels [7, 9, 11,
12]. Auxora, the novel intravenously administered
nanoemulsion formulation of CM4620, rapidly distributes to the lungs and blocks CRAC channel-dependent
cytokine release within hours of its administration [15].
Based on these data and rationale, Auxora was investigated in patients with severe or critical COVID-19 pneumonia. The interim analyses presented here describe the
safety of Auxora for all patients enrolled in the study;
the efficacy analysis is limited to those with severe
COVID-19 pneumonia.

Methods
Patient selection

This phase 2, randomized, controlled, open-label study
was conducted across three centers in the USA (ClinicalTrials.gov number NCT04345614). Patient enrolment
took place from April 8, 2020, to May 13, 2020. Eligible
patients were adults with a diagnosis of COVID-19 determined by reverse transcription polymerase chain reaction and pneumonia documented by chest imaging. In
addition, patients were required to have ≥ 1 symptom
consistent with COVID-19, such as fever, cough, sore
throat, malaise, headache, muscle pain, dyspnea, confusion, or respiratory distress, and ≥ 1 clinical sign suggesting respiratory compromise, such as respiratory rate ≥
30 breaths per minute, heart rate ≥ 125 bpm, SpO2 < 93%
on room air or requiring > 2 L oxygen by nasal cannula
to maintain SpO2 ≥ 93%, or PaO2/FiO2 < 300, imputed
from pulse oximetry or determined by arterial blood gas.
Study design

The initial study design included enrolment of 60 patients receiving low-flow supplemental oxygen at screening into arm A (severe COVID-19 pneumonia) and 60
patients receiving high-flow supplemental oxygen
through a high-flow nasal cannula at screening into arm
B (critical COVID-19 pneumonia). In both arms, patients were randomly assigned in a 2:1 ratio to receive
Auxora plus standard of care or standard of care alone;
randomization was not center specific. Auxora was administered on three consecutive days as a 4-h
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continuous intravenous infusion. The initial dose was
2.0 mg/kg (max 250 mg), and subsequent doses were 1.6
mg/kg (max 200 mg) at 24 and 48 h. All patients received local standard of care, including antiviral agents,
but investigational therapies and immunosuppressive
medications were not permitted. At the discretion of the
site investigators, patients treated with either Auxora or
standard of care alone were able to receive convalescent
plasma if they required invasive mechanical ventilation.
After admission, patients were assessed daily for the first
10 days and then every 48 h until day 28 or discharge,
whichever occurred first. On day 30, all patients were
assessed for mortality. Discharged patients were contacted
by phone. All adverse events (AEs) and serious adverse
events (SAEs) were recorded during hospitalization. The
SpO2 and FiO2 at the time of the study visit and the lowest
SpO2/FiO2 ratio documented over the previous 24 h were
recorded daily. The patient’s clinical status was also evaluated daily by assessing if the patient was alive and required
invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), high-flow supplemental oxygen or non-invasive ventilation, low-flow supplemental
oxygen, or other ongoing medical care in the previous 24
h. The need for continued supplemental oxygen was also
assessed at the time of discharge.
The trial protocol was approved by an institutional review board at each site and was overseen by an independent safety review committee (ISRC). Informed
consent was obtained from either the patient or from
the patient’s legally authorized representative if the patient was unable to provide consent. The ISRC was
scheduled to perform a review for each arm after the
first 12 patients were dosed with Auxora and then again
after 24 patients were dosed. The analysis plan called for
a separate evaluation of the safety and efficacy of the
two arms as enrolment rates were expected to differ.
The ISRC conducted an initial review on May 3, 2020,
after the first 12 patients in arm A were dosed with Auxora. At that time, six patients had received standard of
care in arm A. The ISRC recommended continuing the
trial without changes. The US Food and Drug Administration (FDA) was sent the interim efficacy data presented
here in response to questions about the ISRC review. The
FDA provided guidance on May 12, 2020, to limit further
enrolment in the open-label study and transition to a randomized, blinded, placebo-controlled study, and as such,
both arms A and B ceased further enrolment.
Statistical analysis

All analyses were conducted in the intention-to-treat
population. The primary objective was to determine the
safety and tolerability of Auxora for patients with severe
and critical COVID-19 pneumonia. The incidence, intensity, and relationship of AEs and SAEs and the
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development of laboratory abnormalities that were clinically significant and required intervention were
assessed. Mortality at day 30 was evaluated as a safety
outcome. For the purpose of safety and outcome analyses, patients from arms A and B were analyzed together, comparing treatments with Auxora and standard
of care with standard of care alone.
Efficacy outcome measures included recovery rate defined as the first day the patient satisfied criterion 6, 7,
or 8 of the 8-point ordinal scale (Table 1). Additional
efficacy outcome measures included the change in the 8point ordinal scale over time, the proportion of patients
requiring invasive mechanical ventilation, and a composite outcome of death or invasive mechanical ventilation.
Pre-specified efficacy analyses were performed on enrolled patients with severe COVID-19 pneumonia (arm
A) and in 3 subgroups of arm A according to their baseline PaO2/FiO2 (1–100, 101–200, or ≥ 201). Baseline
PaO2/FiO2 was defined as the lowest value in the 24 h
prior to screening. The PaO2 was imputed from the
SpO2 using a published table based on Ellis’s inversion
of the Severinghaus equation [16, 17].

Results
Patients

At the time of cessation, 30 patients had been enrolled
in the study. Of the 26 patients in arm A, 17 were randomized to treatment with Auxora and nine to standard
of care alone. Four patients were enrolled in arm B:
three to treatment with Auxora and one to standard of
care alone (Fig. 1). Across both arms, 18 patients (90%)
received three doses of Auxora as assigned. One patient
in arm A received only one Auxora dose due to rapid
improvement and early discharge. One patient in arm B
refused the third dose of Auxora. One patient in arm B,
who received all three doses, was transferred after 120 h
to another institution; their outcome was followed by
the initial study team. In the standard of care group of
arm A, one patient withdrew from the study at 96 h after
being made do not intubate (DNI) because of declining
respiratory status. This patient was not included in the
intubation analysis (Fig. 1). All patients who did not die
in the hospital completed the day 30 assessment.
Baseline demographics were balanced across the Auxora and standard of care groups in arm A (Table 2), but
more patients in the Auxora group had diabetes (47%)
than those in the standard of care group (22%). The median time (min, max) from symptom onset to
randomization was 9 (4, 34) days in the Auxora group
and 7 (4, 11) days in the standard of care group. The
baseline mean imputed PaO2/FiO2 was 178 ± 74 in the
Auxora group and 168 ± 78 in the standard of care
group. In arm B, baseline characteristics were more variable due to the small sample size (Table 1). Individual
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Table 1 Eight-point ordinal scale
Scale Description
1

Death

2

Hospitalized, requiring invasive mechanical ventilation or ECMO

3

Hospitalized, requiring non-invasive mechanical ventilation or
high-flow supplemental oxygen

4

Hospitalized, requiring low-flow supplemental oxygen

5

Hospitalized, not requiring supplemental oxygen but requiring
ongoing medical care

6

Hospitalized, not requiring supplemental oxygen or ongoing
medical care

7

Discharged, requiring supplemental oxygen

8

Discharged, not requiring supplemental oxygen

Efficacy outcome measured with the 8-point ordinal scale included recovery
rate defined as the first day the patient satisfied criterion 6, 7, or 8 and change
in the 8-point ordinal scale over time
ECMO extracorporeal membrane oxygenation

patient listings for arm A are presented in the supplementary appendix Figure S1.
Fewer patients randomized to Auxora versus standard
of care received steroids (47% versus 78%) or remdesivir
(18% versus 33%) during the course of the study. Convalescent plasma was administered to 2 patients randomized
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to Auxora, while it was administered in all 4 patients randomized to standard of care who needed mechanical
ventilation.

Safety outcomes

Across both arms, 15 patients (75%) receiving Auxora
had ≥ 1 AE and six patients (30%) had ≥ 1 SAE. Site investigators judged three AEs, each occurring in three different patients, as being related to the administration of
Auxora: an episode of itching, an increase in alkaline
phosphate, and a rash. They were all considered mild by
the investigators and resolved. None of the reported
SAEs was determined to be related to the administration
of Auxora. Among patients receiving standard of care,
eight (80%) had ≥ 1 AE and five (50%) had ≥ 1 SAE.
There was no difference in AEs related to infections in
the Auxora group when compared to standard of care
(30% in each group).
Two patients (10%) treated with Auxora and two patients (20%) receiving standard of care died while hospitalized between 10 and 17 days after randomization
(supplementary appendix Figure S1). There were no
deaths in the 30 days after randomization for patients

Fig. 1 Patient enrolment and randomization. One patient in arm A received only 1 Auxora dose due to rapid improvement and early discharge,
and 1 patient in arm B refused the third dose of Auxora. One patient in arm B, who received all 3 doses, was transferred after 120 h to another
institution. In the standard of care group of arm A, 1 patient withdrew from the study at 96 h after being made do not intubate (DNI) because of
declining respiratory status
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Table 2 Baseline demographics and clinical characteristics
Arm B†

Arm A*
Auxora (n = 17)

SOC (n = 9)

Auxora (n = 3)

SOC (n = 1)

Age, years (mean ± SD)

59 ± 12

61 ± 13

64 ± 14

36 ± NA

Median BMI, kg/m2 (min, max)

30 (25, 79)

30 (23, 49)

23 (18, 36)

34

Male sex, n (%)

7 (41)

5 (56)

1 (33)

1 (100)

8 (47)

5 (56)

1 (33)

0

Ethnicity, n (%)
White
Black or African American

7 (41)

3 (33)

1 (33)

1 (100)

Asian

0

1 (11)

1 (33)

0

2 (12)

0

0

0

Hispanic or Latino, n (%)

Others/multiple

2 (12)

1 (11)

0

0

Diabetes, n (%)

8 (47)

2 (22)

2 (67)

0 (0)

Hypertension, n (%)

8 (47)

4 (44)

2 (67)

0 (0)

Median time from the onset of symptoms
to randomization, days (min, max)

9 (4, 34)

7 (4, 11)

11 (8, 17)

13

Ferritin, ng/mL (mean ± SD)

709 ± 553

772 ± 742

1776 ± 722

2151 ± NA

CRP, mg/dL (mean ± SD)

10 ± 7

12 ± 6

14 ± 11

9 ± NA

PaO2/FiO2 (mean ± SD)

178 ± 74

168 ± 78

106 ± 45

87 ± NA

PaO2/FiO2 ≥ 201

7 (41)

3 (33)

0

0

PaO2/FiO2 101–200

6 (35)

4 (44)

2 (67)

0

PaO2/FiO2 ≤ 100

4 (24)

2 (22)

1 (33)

1 (100)

PaO2/FiO2 101–200 ferritin ng/mL (mean ± SD)

867 ± 712

910 ± 1090

1637 ± 963

NA

PaO2/FiO2 101–200 CRP mg/dL (mean ± SD)

11 ± 5

13 ± 9

16 ± 15

NA

Baseline demographics were balanced across the Auxora and standard of care groups in arm A. In arm B, baseline characteristics were more variable due to the
small sample size
NA not available, SOC standard of care
*Patients in arm A included those who were receiving low-flow supplemental oxygen at screening and were defined by regulatory guidance as having severe
COVID-19 pneumonia
†
Patients in arm B were defined by regulatory guidelines as having critical COVID-19 pneumonia

who were discharged from the hospital. Both patients in
the Auxora group and one patient in the standard of
care group died while receiving invasive mechanical ventilation. The other patient receiving standard of care
who died had been made DNI.
Efficacy outcomes

Patients with severe COVID-19 pneumonia (arm A)
treated with Auxora had a shorter median time to recovery (5 days) than patients treated with standard of care
(12 days); the recovery rate ratio was 1.87 (95% confidence
interval [CI], 0.72 to 4.89; Fig. 2). In addition, three of 17
patients treated with Auxora (18%) were intubated compared to four of eight (50%) assigned to standard of care
(95% CI, − 0.07 to 0.71). The reduction was most pronounced in patients with a baseline PaO2/FiO2 between
101 and 200, in which only one of six patients (17%)
treated with Auxora required intubation compared to
three of four patients (75%) assigned to standard of care.
No patients receiving Auxora or standard of care with a
baseline PaO2/FiO2 > 200 required invasive mechanical

ventilation. A composite endpoint of death or invasive
mechanical ventilation occurred less frequently in patients
treated with Auxora (18%) compared to those assigned to
standard of care (56%) with a hazard ratio of 0.23 (95% CI,
0.05 to 0.96; P < 0.05; Fig. 3).
Clinical improvement, as measured by the mean of an
8-point ordinal scale, was greater in the Auxora group
starting at day 4, reaching statistical significance on day
6, and remained significant from day 9 to day 12 (P <
0.05; Fig. 4). On day 4, the odds ratio for clinical deterioration on the 8-point ordinal scale for the Auxora
group compared to the standard of care group was 0.21
(95% CI, 0.04 to 0.098; P < 0.05). The clinical improvement was most pronounced in patients with a baseline
PaO2/FiO2 between 101 and 200, with the difference in
means reaching statistical significance at day 7; this was
maintained through day 12 (P < 0.05; Fig. 5).

Discussion
In this phase 2, open-label, randomized, multicenter
study of patients with severe or critical COVID-19
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Fig. 2 Recovery rate among patients with severe COVID-19 pneumonia. Recovery rate defined as the first day the patient satisfied criterion 6, 7,
or 8 of the 8-point ordinal scale. Patients receiving Auxora had a shorter median time to recovery (5 days) than patients treated with standard of
care (12 days); recovery rate ratio was 1.87 (95% CI, 0.72 to 4.89). Patients with severe COVID-19 pneumonia were receiving low-flow supplemental
oxygen (arm A)

pneumonia, Auxora, a novel, intravenously administered
CRAC channel inhibitor, demonstrated a potential
therapeutic benefit in mitigating the respiratory complications of COVID-19. At the recommendation of the US
FDA, this study was halted prior to completion of the
originally planned 120 patients in order to transition to
a randomized, placebo-controlled, double-bind study.

CRAC channel activation in the pulmonary endothelium is linked to the breakdown of the alveolar-capillary
barrier [7–9]. CRAC channel activation also initiates the
production and release of proinflammatory cytokines
from immune cells [10, 11]. The resulting development
of pulmonary edema, hypoxemia, and ultimately ARDS
contributes to the significant morbidity and mortality

Fig. 3 Percentage of patients with severe COVID-19 pneumonia reaching a composite endpoint. The composite endpoint was defined as needing
invasive mechanical ventilation or death in the 30 days after randomization. Hazard ratio was 0.23 (95% CI, 0.05 to 0.96; P < 0.05). Patients with severe
COVID-19 pneumonia were receiving low-flow supplemental oxygen (arm A)
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Fig. 4 Eight-point ordinal scale over time in patients with severe COVID-19 pneumonia. The mean difference was statistically significant for
Auxora (n = 17) when compared with standard of care (n = 9) at day 6 and days 9 through 12 (*P < 0.05 versus standard of care). Patients with
severe COVID-19 pneumonia were receiving low-flow supplemental oxygen (arm A)

seen in COVID-19 pneumonia, particularly in those who
eventually require invasive mechanical ventilation [14, 18].
As demonstrated in animal models, inhibition of CRAC
channels stabilizes pulmonary endothelial cells, blocks the
release of proinflammatory cytokines, and decreases
vascular inflammation and permeability [7, 9, 14]. Given
the direct effects on the pulmonary endothelium and the
indirect effects on proinflammatory cytokine production,

Auxora may be an attractive therapy for the management
of patients with severe COVID-19 pneumonia [7–9].
Auxora has also demonstrated rapid distribution to the
lungs, resulting in a fast onset of action that is reversible
in 24 to 48 h (unpublished observations).
The data available at the time of study termination indicate an encouraging safety profile for Auxora, with no
increase in the proportion of patients experiencing AEs or

Fig. 5 Eight-point ordinal scale in patients with severe COVID-19 pneumonia with PaO2/FiO2 between 101 and 200. The mean difference was
statistically significant from day 7 to day 12 for patients receiving Auxora (n = 6) compared with those receiving standard of care (n = 4; *P < 0.05
versus standard of care). Patients with severe COVID-19 pneumonia were receiving low-flow supplemental oxygen (arm A)
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SAEs when compared with standard of care. Furthermore,
while the sample size was small, patients receiving Auxora
appeared to have a more favorable clinical course than patients receiving standard of care as reflected by the rapid
time to recovery; the decreased need for steroids, remdesivir, convalescent plasma, or invasive mechanical ventilation; and greater improvement in clinical outcomes as
documented by the difference in 8-point ordinal scale.
Analysis of the ordinal scale over time also suggested
greater odds of improvement in patients treated with Auxora beginning on day 4, with the most pronounced clinical
benefit in patients with a PaO2/FiO2 ratio between 101
and 200. These efficacy signals will need to be confirmed
in a larger, double-blind, placebo-controlled study.
The ideal timing and duration of intervention in the
course of COVID-19 pneumonia remain unknown [19].
There are some concerns that premature immunomodulation may inhibit host antiviral immunity and delay viral
clearance, while delaying immunomodulation may prove
futile if acute pulmonary injury is advanced. The PaO2/
FiO2 ratio, imputed from the SpO2/FiO2, could serve as
a simple means of determining both the optimal timing
of intervention and the patients most likely to benefit
[16, 17]; it should be incorporated into other studies of
therapies for COVID-19. Currently, patients are only being categorized by the receipt of either low-flow supplemental oxygen or high-flow supplemental oxygen, but
this approach may not capture the severity of lung injury, may mask patients who are likely to respond to
treatment, and is limited by substantial inter-institution
variations in practice.
Our findings, and those from recent remdesivir and RECOVERY trials, raise consideration for a two-pronged approach for the treatment of COVID-19 pneumonia [19, 20].
Preliminary results of remdesivir for the treatment of
COVID-19 demonstrated reduced time to recovery, but
treatment alone with an antiviral therapy is unlikely to be
sufficient in improving outcomes [19]. It may be possible,
however, to improve patient outcomes by combining an antiviral treatment with immunomodulation to address the inflammatory response. Results from the RECOVERY trial
demonstrated that after up to 10 days of receiving oral or
intravenous dexamethasone once daily, the 28-day mortality
was lower than that in the usual care group among patients
receiving invasive mechanical ventilation (29.3% versus
41.4%, respectively) and among those receiving oxygen
without invasive mechanical ventilation (23.3% versus
26.2%, respectively) [20]. The 28-day mortality rates in the
RECOVERY trial for patients receiving low-flow supplemental oxygen versus high-flow supplemental oxygen
were not presented. Finally, there was a non-significant
decrease in a composite outcome of death or invasive
mechanical ventilation among patients not receiving invasive mechanical ventilation at randomization who were
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treated with dexamethasone compared to those treated
with usual care (25.6% versus 27.3%, respectively) [20]. As
Auxora is associated with a rapid onset of action and a
rapid cessation of action, it appears to work quickly to reduce proinflammatory cytokines while preserving pulmonary endothelial integrity, without excessive
immunosuppression [15] but further research is needed in
patients with severe COVID-19 pneumonia. Coupled with
the low 28-day mortality rate (10%) presented here, Auxora may allow for improved patient outcomes when used
in combination with dexamethasone. Additional clinical
trials are needed to understand the effect of these combinations of therapy.
The interpretation of the results of this study is limited
by the open-label design and small sample size. Additionally, the significant imbalances in age and medical comorbidities between the three patients receiving Auxora and
one patient receiving standard of care in arm B prevented
a meaningful direct comparison between the two groups
with critical COVID-19 pneumonia. It was observed that
the proportion of patients treated with Auxora who had
diabetes, a co-morbidity associated with poorer outcomes
in COVID-19, was double that for patients receiving
standard of care alone. Manufacturing and administration
of a placebo were sacrificed given the need to initiate the
study rapidly during the global pandemic with associated
constraints on healthcare resources. These constraints,
including adequate personal protective equipment, also
limited the ability of research teams to obtain researchspecific cytokine levels, which if obtained, may have further supported the mechanisms of Auxora.

Conclusions
In this preliminary, phase 2 study of the novel CRAC inhibitor, Auxora, the observed favorable safety profile and efficacy
signals when compared to standard of care support the need
for further investigation in a large, double-blind, placebocontrolled trial in patients with severe COVID-19 pneumonia. In addition, these results suggest the potential for the
clinical development of Auxora for the treatment of other
etiologies of acute respiratory distress syndrome. A randomized, placebo-controlled, double-blind study will soon be underway to test the efficacy of Auxora in combination with
local standard of care, likely remdesivir and/or dexamethasone, for the management of patients with severe COVID-19
pneumonia.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13054-020-03220-x.
Additional file 1. Supplementary Appendix: Auxora versus standard of
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